Anzeige
Mehr »
Freitag, 22.05.2026 - Börsentäglich über 12.000 News
Nach dem Tungsten-Schock: Startet hier jetzt die nächste große US-Critical-Minerals-Story?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3EWWS | ISIN: CA27966L3065 | Ticker-Symbol: RBT
Tradegate
21.05.26 | 18:06
9,300 Euro
-1,59 % -0,150
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
EDESA BIOTECH INC Chart 1 Jahr
5-Tage-Chart
EDESA BIOTECH INC 5-Tage-Chart
RealtimeGeldBriefZeit
9,1009,60021.05.

Aktuelle News zur EDESA BIOTECH Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
14.05.Edesa Biotech, Inc. - 10-Q, Quarterly Report4
EDESA BIOTECH Aktie jetzt für 0€ handeln
14.05.Edesa Biotech, Inc. - 8-K, Current Report2
14.05.Edesa Biotech, Inc.: Edesa Biotech Reports Fiscal 2nd Quarter 2026 Results246TORONTO, May 14, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases...
► Artikel lesen
14.05.Edesa Biotech GAAP EPS of -$0.491
26.03.Edesa Biotech, Inc.: Edesa Biotech Advances Vitiligo Program for Planned Mid-2026 Enrollment13
24.02.Edesa Biotech reports mortality reduction in phase 3 trial36
24.02.Edesa Biotech, Inc. - 8-K, Current Report3
24.02.Edesa Biotech, Inc.: Edesa Biotech Reports Additional Positive Results from Phase 3 Paridiprubart Study599Results in a population of 278 patients affirm statistically significant mortality reductionsBenefits observed across severity groups and in subjects with serious comorbiditiesCompany files provisional...
► Artikel lesen
13.02.Edesa Biotech, Inc. - 10-Q, Quarterly Report3
13.02.Edesa Biotech reports FQ1 net loss of $2.2 million1
13.02.Edesa Biotech, Inc. - 8-K, Current Report1
13.02.Edesa Biotech, Inc.: Edesa Biotech Reports Fiscal 1st Quarter 2026 Results780TORONTO, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases...
► Artikel lesen
15.12.25Edesa Biotech GAAP EPS of -$1.27 beats by $0.512
12.12.25Edesa Biotech erweitert "At-the-Market"-Angebot auf 2,26 Millionen US-Dollar2
12.12.25Edesa Biotech, Inc.: Edesa Biotech Reports Fiscal Year 2025 Results331TORONTO, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases...
► Artikel lesen
12.12.25Edesa Biotech, Inc. - 10-K, Annual Report-
12.12.25Edesa Biotech, Inc. - 8-K, Current Report-
28.10.25Edesa Biotech, Inc.: Edesa Biotech Reports Positive Results in Phase 3 Respiratory Study576Study met primary and secondary endpointsParidiprubart demonstrated a relative reduction in the risk of death of 25%Treatment provided patients with clinically meaningful improvement in survival and...
► Artikel lesen
08.08.25Edesa Biotech, Inc.: Edesa Biotech Reports Fiscal 3rd Quarter 2025 Results465TORONTO, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases...
► Artikel lesen
19 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1